CureVac N.V. (CVAC) Financials

NASDAQ:CVAC

Market Cap

1.73B

Total Revenue

67.42M

Gross Profit

-116.57M

Operating Income

-249.46M

Net Income

-249.03M

Metric	2018	2019	2020	2021	2022
revenue	12,871,000	17,416,000	48,900,000	102,990,000	67,420,000
costOfRevenue	17,744,000	27,983,000	14,173,000	238,195,000	183,993,000
grossProfit	-4,873,000	-10,567,000	34,727,000	-135,205,000	-116,573,000
researchAndDevelopmentExpenses	41,722,000	43,242,000	113,808,000	815,907,000	62,550,000
sellingAndMarketingExpenses	1,085,000	1,755,000	733,000	1,743,000	417,000
generalAndAdministrativeExpenses	20,415,000	42,183,000	45,029,000	87,201,000	88,994,000
sellingGeneralAndAdministrativeExpenses	21,500,000	43,938,000	45,762,000	88,944,000	89,411,000
operatingExpenses	67,951,000	88,930,000	158,700,000	277,058,000	134,279,000
operatingIncome	-72,824,000	-99,498,000	-124,002,000	-412,263,000	-249,457,000
totalOtherIncomeExpensesNet	1,693,000	-627,000	-5,798,000	-235,000	302,000
ebitda	-67,075,000	-91,501,000	-109,800,000	-386,486,000	-223,102,000
depreciationAndAmortization	3,781,000	7,997,000	14,202,000	25,777,000	26,355,000
interestIncome	1,968,000	833,000	2,070,000	10,103,000	4,009,000
interestExpense	275,000	1,460,000	22,103,000	10,338,000	3,707,000
incomeBeforeTax	-71,131,000	-100,125,000	-129,800,000	-412,498,000	-249,155,000
incomeTaxExpense	110,000	-252,000	-726,000	-782,000	-126,000
netIncome	-71,241,000	-99,873,000	-129,074,000	-411,716,000	-249,029,000
eps	-0.4	-0.57	-0.72	-2.21	-1.32
epsdiluted	-0.4	-0.57	-0.72	-2.21	-1.32
weightedAverageShsOut	175,968,204	175,968,204	180,460,565	186,012,586	189,074,911
weightedAverageShsOutDil	175,968,204	175,968,204	180,460,565	186,012,586	189,074,911
costAndExpenses	85,695,000	116,913,000	158,700,000	515,253,000	318,272,000
otherExpenses	4,729,000	1,750,000	-870,000	-627,793,000	-17,682,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Tübingen, , DE

Website

curevac.com

CEO

Dr. Alexander Zehnder M.B.A., M.D.

Employees

904

About the Company

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.